Alto Neuroscience, Inc. (NYSE:ANRO) Given Consensus Rating of “Moderate Buy” by Analysts

Alto Neuroscience, Inc. (NYSE:ANRO) has received an average rating of “Moderate Buy” from the eight ratings firms that are presently covering the stock, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $20.00.

Several equities research analysts recently commented on the company. RODMAN&RENSHAW cut Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Stifel Nicolaus reduced their price target on Alto Neuroscience from $32.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. Wedbush lowered shares of Alto Neuroscience from an “outperform” rating to a “neutral” rating and dropped their price objective for the company from $29.00 to $4.00 in a report on Wednesday, October 23rd. Robert W. Baird cut their price objective on shares of Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Finally, Rodman & Renshaw lowered shares of Alto Neuroscience from a “buy” rating to a “neutral” rating in a report on Wednesday, October 23rd.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Geode Capital Management LLC increased its position in shares of Alto Neuroscience by 148.7% during the third quarter. Geode Capital Management LLC now owns 469,988 shares of the company’s stock valued at $5,378,000 after acquiring an additional 281,018 shares during the last quarter. State Street Corp increased its holdings in Alto Neuroscience by 123.7% in the 3rd quarter. State Street Corp now owns 236,857 shares of the company’s stock valued at $2,710,000 after purchasing an additional 130,985 shares during the last quarter. Jennison Associates LLC increased its holdings in Alto Neuroscience by 80.3% in the 3rd quarter. Jennison Associates LLC now owns 832,290 shares of the company’s stock valued at $9,521,000 after purchasing an additional 370,612 shares during the last quarter. Franklin Resources Inc. raised its position in Alto Neuroscience by 95.3% in the third quarter. Franklin Resources Inc. now owns 1,220,712 shares of the company’s stock valued at $13,965,000 after purchasing an additional 595,673 shares during the period. Finally, Jane Street Group LLC acquired a new position in Alto Neuroscience during the third quarter worth $124,000.

Alto Neuroscience Stock Up 5.1 %

NYSE ANRO opened at $4.21 on Friday. Alto Neuroscience has a one year low of $3.56 and a one year high of $21.64. The company has a debt-to-equity ratio of 0.05, a current ratio of 13.10 and a quick ratio of 13.09. The business has a fifty day moving average price of $4.23 and a 200 day moving average price of $7.94.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.05. On average, equities research analysts forecast that Alto Neuroscience will post -2.54 EPS for the current fiscal year.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.